Quigley David 4

What Happened
David Quigley, elected to the CervoMed (CRVO) board, received a grant (derivative award) of an option to purchase 8,150 shares of common stock on June 8, 2026. The grant was reported with a $0 cash price in the Form 4; the award vests monthly over one year in 1/12th increments beginning June 30, 2026, subject to continued service.

Key Details

• Transaction date: June 8, 2026 (Period of Report: 2026-06-08)
• Filing date: June 10, 2026 (Form 4 accession 0001437749-26-020215) — filed within the normal 2-business-day window.
• Transaction type/code: Grant/Award (A) — option (derivative) to purchase 8,150 shares. Reported price: $0 (no cash paid at grant).
• Vesting: Monthly over one year in substantially equal 1/12th increments on the last day of each month starting 6/30/2026; subject to continued service.
• Footnote: Award made in connection with Reporting Person’s election to the board and under the Issuer’s 2025 Equity Incentive Plan per the non-employee director compensation policy.
• Shares owned after transaction: Not specified in the provided filing.

Context
This was an equity compensation grant to a newly elected non-employee director (typical director pay), not an open-market purchase or sale. Grants of options are common to align director incentives and do not necessarily indicate immediate bullish or bearish sentiment. As a derivative award, the option gives the right to buy shares subject to vesting and any future exercise conditions; no shares were sold or exercised in this filing.